世界卫生组织关于早产或低出生体重儿照护的新建议:卫生政策
世界卫生组织(WHO)于2021年召集指南发展小组(GDG),按WHO指南评审委员会(GRC)标准审查证据,采用GRADE方法评估证据确定性,并用DECIDE框架形成判断,共提出25条建议(11条新建议,16条为预防与促进照护建议)。新建议包括:咖啡因治疗呼吸暂停与拔管、家庭参与常规照护、出院后家访随访、考虑使用益生菌、润肤治疗、咖啡因预防呼吸暂停、胎龄小于32周婴儿出生后立即使用持续气道正压(CPAP)(不论有无呼吸窘迫),以及家庭支持以保障早产或低出生体重儿照护。KMC被推荐作为所有早产或低出生体重新生儿的常规照护,出生后立即开始,机构与家庭均可实施,但休克、复苏后不能自主呼吸或需通气支持的危重儿除外。这些建议确认了预防与促进照护的关键作用,尤其强调母婴同室及赋权家庭参与照护;WHO正推动小与患病新生儿照护的扩大,包括基础设施、药品耗材、人力与监测等卫生系统构建模块的组织转变。
要点
- WHO推荐KMC作为所有早产或低出生体重新生儿的常规照护,出生后立即开始,机构与家庭均可实施。
- KMC不适用于危重儿:休克、复苏后不能自主呼吸或需通气支持的早产或低出生体重儿。
- 新建议:对早产或低出生体重儿,咖啡因用于治疗呼吸暂停及拔管,并考虑用于预防呼吸暂停。
- 新建议:胎龄小于32周婴儿出生后立即使用CPAP,不论有无呼吸窘迫。
- 新建议:家庭参与常规照护、出院后家访随访、家庭支持,以及考虑益生菌与润肤治疗。
适用人群与场景
- 早产或低出生体重(LBW)新生儿,覆盖低、中、高收入国家。
- KMC适用人群为所有早产或LBW新生儿,除外危重儿(休克、复苏后不能自主呼吸或需通气支持)。
- 胎龄小于32周婴儿出生后立即使用CPAP的推荐人群。
处置流程与药物剂量
- KMC:出生后立即开始,作为所有早产或LBW新生儿的常规照护,机构与家庭均可实施;危重儿(休克、复苏后不能自主呼吸或需通气支持)除外。
- 咖啡因:用于治疗早产或LBW婴儿呼吸暂停,并用于拔管;另可考虑用于预防呼吸暂停。
- CPAP:胎龄小于32周婴儿出生后立即使用,不论有无呼吸窘迫。
- 家庭参与:家庭参与早产或LBW婴儿的常规照护,并提供家庭支持以保障照护。
- 出院后随访:出院后家访随访照护。
- 其他可考虑措施:益生菌、润肤治疗。
红旗征与不能漏的情况
- 休克、复苏后不能自主呼吸或需通气支持的早产或LBW婴儿为KMC例外,不启动KMC。
研究设计与关键结果
- WHO于2021年召集指南发展小组(GDG),按WHO指南评审委员会(GRC)标准审查证据,采用GRADE方法评估证据确定性,并用DECIDE框架形成判断,共提出25条建议,其中11条为新建议,16条为预防与促进照护建议。
- 新建议涵盖:咖啡因治疗呼吸暂停与拔管、家庭参与常规照护、出院后家访随访、考虑益生菌、润肤治疗、咖啡因预防呼吸暂停、胎龄小于32周婴儿出生后立即使用CPAP(不论有无呼吸窘迫)、家庭支持。
- KMC被推荐为所有早产或LBW新生儿的常规照护,出生后立即开始,机构与家庭均可实施,危重儿除外。
- 建议确认预防与促进照护的关键作用,强调母婴同室及赋权家庭照护;WHO正推动小与患病新生儿照护的扩大,包括基础设施、药品耗材、人力与监测等卫生系统构建模块的组织转变。
证据类型、等级与局限
- 证据类型:世界卫生组织(WHO)指南,采用GRADE方法评估证据确定性,并使用DECIDE框架形成判断。
- 推荐强度:原文未逐条给出推荐强度标签。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对早产或LBW新生儿,出生后立即启动KMC作为常规照护,机构与家庭均可实施,但休克、复苏后不能自主呼吸或需通气支持的危重儿除外。
- 对早产或LBW婴儿,咖啡因可用于治疗呼吸暂停及拔管,并可考虑用于预防呼吸暂停。
- 对胎龄小于32周婴儿,出生后立即使用CPAP,不论有无呼吸窘迫。
- 将家庭参与常规照护、出院后家访随访及家庭支持纳入早产或LBW婴儿照护。
- 可考虑使用益生菌与润肤治疗。
指南或共识出处
- 世界卫生组织(WHO)2021年关于早产或低出生体重儿照护的建议。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Approximately 11% of infants are born preterm, and complications of prematurity are the most common cause of death in children aged under five years. Almost one million preterm infants die each year across low, high and middle income countries. In 2021, the World Health Organization (WHO) convened a Guideline Development Group (GDG) to examine evidence and formulate recommendations for care of preterm or low birthweight (LBW) infants according to WHO Guideline Review Committee (GRC) criteria. GRADE methods were used to assess the certainty of evidence and the GDG developed judgements using the DECIDE (Developing and Evaluating Communication strategies to support Informed Decisions and practice based on Evidence) framework. Twenty-five recommendations were made; 11 recommendations were new, and 16 were for preventive and promotive care. Kangaroo Mother Care (KMC) was recommended to start immmediately after birth as routine care for all preterm or LBW newborns (except for critically ill infants who are in shock, unable to breath spontaneously after resuscitation, or require ventilatory support) both in the facility and at home. New recommendations were also made for caffeine to treat apnoea and for extubation; family involvement in routine care for preterm or LBW infants; and for post-discharge home-visit follow-up care. New recommendations were also made to consider use of probiotics, emollient therapy, caffeine for prevention of apnoea, continuous positive airway pressure (CPAP) immediately after birth (with or without respiratory distress) in infants less than 32 weeks gestational age; and for family support to enable the care of preterm or LBW infants. The recommendations confirm the pivotal role of preventive and promotive care for preterm and LBW infants, especially the importance of keeping the baby and mother together, and empowering and supporting families to care for their preterm or LBW infant. WHO is now working to help scale up care for small and sick newborns, including organizational shifts in all 'health system building blocks' such as infrastructure, commodities, workforce and monitoring.
参考来源
- New World Health Organization recommendations for care of preterm or low birth weight infants: health policy. EClinicalMedicine. 2023. PMID: 37753445. doi:10.1016/j.eclinm.2023.102155
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。